Ocrevus vs Skyrizi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Skyrizi costs 81% less per claim than Ocrevus ($4475.00 vs $23635.00). Ocrevus has a generic alternative available. Total Medicare spending: Ocrevus at $3.5B vs Skyrizi at $2.3B.
| Metric | Ocrevus | Skyrizi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $23,635 | $4,475* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.5B | $2.3B |
| Total Claims | 148,000 | 524,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 16.5%* | 42.8% |
| Generic Available | Yes | No |
| Condition | Multiple Sclerosis | Autoimmune Diseases |
| Total Beneficiaries | 62,000 | 78,000 |
Skyrizi costs 81% less per claim than Ocrevus ($4475.00 vs $23635.00). Ocrevus has a generic alternative available. Total Medicare spending: Ocrevus at $3.5B vs Skyrizi at $2.3B.
Explore More
Comparing Ocrevus and Skyrizi on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Ocrevus and Skyrizi detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.